trk-950
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 23, 2017 (NCT02990481)
Timeline
Indications
Studied for
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Cholangiocarcinoma · Phase 1
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Melanoma · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Stomach Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594360 ↗
Also known as
- trk-950
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06038578 | Phase 2 | Oct 4, 2023 | Toray Industries, Inc |
| NCT05423262 | Phase 1 | Jul 6, 2022 | Toray Industries, Inc |
| NCT03872947 | Phase 1 | Apr 26, 2019 | Toray Industries, Inc |
| NCT02990481 | Phase 1 | Feb 23, 2017 | Toray Industries, Inc |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Toray Industries, Inc | For profit | 4 | 4 | 2 | 2017 |
1 organizations
Page 1 / 1